Technical Data
C0115-02
Calcitonin Gene-Related Peptide (CGRP)
Description:
Calcitonin leads to a lowering of plasma calcium and phosphate levels via the inhibition of bone resorption and excretion through the kidneys. Calcitonin is found in C cells of the normal and hyperplastic thyroid.

The calcitonin family of bioactive peptides comprises of calcitonin, amylin, two calcitonin-gene related peptides (CGRP1, and CGRP2) and adrenomedullin (ADM). Calcitonin is 32aa peptide found in the parafollicular "C" cells of the thyroid in mammals. It is also found in a number of non-mammals. It regulated the mineral (calcium and phosphate) balance. Calcitonin causes hypercalcemia by acting as an inhibitor of osteoclast induced bone resorption. CGRP is a 37-aa peptide produced by tissue specific processing of the calcitonin gene.

Calcitonin is the major product in the thyroid, whereas CGRP is the major product in neural tissues. CGRP is a potent cardiovascular agent. It has structural similarity with amylin. CGRP is found in two isoforms (CGRP-I and CGRP-II) that differs only by 3 amino acids. Amylin is a 37-aa peptide produced in the pancreatic beta-cell secretory granules and is co-released with insulin. Amylin also has CGRP-like effects on bone metabolism. Amylin has specific binding sites in the CNS and it may regulate gastric emptying and influence carbohydrate metabolism. Adrenomedullin (ADM) is a 52-aa hypotensive peptide. It has structural similarity with CGRP and amylin. ADM is produced in peripheral tissues, adrenal medulla, lung, and kidney. ADM has specific receptors on astrocytes and it is unregulated in ischaemia.

The calcitonin family peptides probably act through G-protein coupled membrane receptors. Recently, a homolog of calcitonin receptor, CRLR (calcitonin-receptor-like receptor human 461 aa; rat/mouse 463 aa) was identified. It is now shown that CRLR can function as either a CGRP receptor or an ADM receptor, depending upon which members of a new family of proteins called receptor activity modifying proteins (RAMP1-3) are expressed.

Applications:
Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
ELISA: 0.5-1ug/ml. Control peptide can be used to coat ELISA plates at 1ug/ml .
Western Blot: 1-10ug/ml using ECL technique.

Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ul-20CBlue IceHumanRabbit
Concentration:
As reported
Immunogen:
19aa peptide mapping to the C-terminal region of human CGRP (conjugated to KLH). This region is least conserved in other calcitonin. Species Sequence Homology: Canine (100%), bovine, sheep, rat , chicken, (92%), frog and porcine (85%). There are just 2 aa
Purity:
Purified by immunoaffinity chromatography
Form
Supplied as a powder lyophilized from a solution containing PBS with 0.05% sodium azide. Reconstitute with 100ul sterile PBS.
Specificity:
Recognizes human CGRP
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
(1). Steenbergh et al (1986) FEBS Lett. 209, 97-103; Petermann JB et al (1987) JBC 262, 542-545; Wimalwamsa SJ et al (1990) BBRC 167, 993-1000; Kitamura k et al (1992) BBRC 185, 134-141; McLatchie LM et al (1998) Nature 393, 333-339; Nagae T et al (2000) BBRC 270, 89-93; Husmann, K et al (2000); Mol Cell Endocrinol (2000) 162, 35-43